AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.
Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States.
